Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088852 | 0.92 | S1PR1 (0.40) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2324421 | 0.90 | S1PR1 (0.45) | S1PR1ALOX5FFAR1S1PR5XBP1 | |
| SCHEMBL2324410 | 0.89 | CD274 (0.37) | S1PR1ALOX5FFAR1S1PR5S1PR4 | |
| SCHEMBL10089079 | 0.89 | ALOX5 (0.37) | S1PR1ALOX5S1PR5S1PR4HRH3 | |
| SCHEMBL10088881 | 0.88 | FFAR1 (0.37) | S1PR1ALOX5FFAR1S1PR5XBP1 | |
| SCHEMBL10088831 | 0.86 | S1PR1 (0.45) | S1PR1ALOX5S1PR5S1PR4 | |
| SCHEMBL10088855 | 0.85 | CD274 (0.42) | S1PR1S1PR5S1PR4 | |
| SCHEMBL10089050 | 0.84 | FFAR1 (0.32) | S1PR1ALOX5FFAR1S1PR5 | |
| SCHEMBL17510085 | 0.84 | S1PR1 (0.35) | S1PR1ALOX5FFAR1S1PR5S1PR4 | |
| SCHEMBL10088878 | 0.83 | S1PR1 (0.38) | S1PR1ALOX5S1PR5S1PR4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | S1PR1 1/4885ALOX5 257/4885FFAR1 73/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885ALOX5 377/4885FFAR1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.